Pluristem Therapeutics (PSTI) completes enrollment for a Phase I/II study of its Placental...


Pluristem Therapeutics (PSTI) completes enrollment for a Phase I/II study of its Placental Expanded (PLX-PAD) cells for the treatment of muscles traumatized during hip-replacement surgery. "This trial is important as it marks the first time PLX-PAD cells have been used in patients following surgically induced muscle trauma. It also provides data on the potential use of PLX cells for the treatment of sports related injuries," says Pluristem. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs